Overview

Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion

Status:
Unknown status
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing tacrolimus dose. The primary goal is to assess the change in renal function at 6 and 12 months after conversion using creatinine levels and calculated creatinine clearance. The study will include two groups: The study group of 30 patients and a matched control group with creatinine levels at similar range.
Phase:
Phase 4
Details
Lead Sponsor:
Rabin Medical Center
Collaborator:
Novartis
Treatments:
Everolimus
Sirolimus
Tacrolimus